Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Published:2016-08-10 Issue:2 Volume:37 Page:205-211
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Tacke Frank¹,Günther Rainer²,Buggisch Peter³,Klinker Hartwig⁴,Schober Andreas⁵,John Christine⁶,Lutz Thomas⁷,Pfeiffer-Vornkahl Heike⁸,Niederau Claus⁹,Cornberg Markus¹⁰,Sarrazin Christoph¹¹,Mauss Stefan¹²

Affiliation:

1. Department of Medicine III; University Hospital Aachen; Aachen Germany

2. Universitätsklinikum Schleswig-Holstein (UKSH); Kiel Germany

3. IFI-Institute for Interdisciplinary Medicine; Hamburg Germany

4. University Hospital Würzburg; Würzburg Germany

5. Hepatologische Praxis; Göttingen Germany

6. Hepatologische Praxis; Berlin Germany

7. Infektiologikum; Frankfurt Germany

8. e.factum GmbH; Butzbach Germany

9. St. Josef-Hospital; Katholisches Klinikum Oberhausen; Oberhausen Germany

10. Hannover Medical School; Hannover Germany

11. University Hospital Frankfurt; Frankfurt Germany

12. Center for HIV and Hepatogastroenterology; Duesseldorf Germany

Funder

Deutsches Zentrum für Infektionsforschung

AbbVie Deutschland

Bristol-Myers Squibb Foundation

Gilead Sciences

Janssen-Cilag GmbH

Merck Sharp and Dohme

Roche

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13206/fullpdf

Reference29 articles.

1. Liver transplantation in Germany;Tacke;Liver Transplant,2016

2. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28 809 patients;Vermehren;PLoS ONE,2012

3. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios;Wolffram;J Hepatol,2015

4. Historical epidemiology of hepatitis C virus (HCV) in selected countries;Bruggmann;J Viral Hepatitis,2014

5. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

2. Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis;Infectious Diseases and Therapy;2022-06-24

3. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry;Hepatology Communications;2022-06-05

4. Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients;The Eurasian Journal of Medicine;2022-06-03

5. Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis;Journal of Viral Hepatitis;2022-04-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3